Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 16/20 | 0.57 |
| ▸ | IGF1R | P08069 | 13/20 | 0.57 |
| ▸ | INSR | P06213 | 12/20 | 0.57 |
| ▸ | EGFR | P00533 | 7/20 | 0.57 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.56 |
| ▸ | PTK2B | Q14289 | 4/20 | 0.56 |
| ▸ | MET | P08581 | 3/20 | 0.54 |
| ▸ | STK10 | O94804 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 3/20 | 0.53 |
| ▸ | LCK | P06239 | 3/20 | 0.53 |
| ▸ | FYN | P06241 | 3/20 | 0.53 |
| ▸ | FES | P07332 | 3/20 | 0.53 |
| ▸ | YES1 | P07947 | 3/20 | 0.53 |
| ▸ | HCK | P08631 | 3/20 | 0.53 |
| ▸ | ROS1 | P08922 | 3/20 | 0.53 |
| ▸ | FER | P16591 | 3/20 | 0.53 |
| ▸ | LTK | P29376 | 3/20 | 0.53 |
| ▸ | FLT3 | P36888 | 3/20 | 0.53 |
| ▸ | FRK | P42685 | 3/20 | 0.53 |
| ▸ | BTK | Q06187 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26778373 | 0.88 | ALK (0.69) | ALKIGF1RINSREGFRPTK2 | |
| SCHEMBL24327396 | 0.87 | PTK2 (0.63) | ALKIGF1RINSREGFRPTK2 | |
| SCHEMBL26778364 | 0.87 | ALK (0.77) | ALKIGF1RINSREGFRPTK2 | |
| SCHEMBL24327558 | 0.86 | ALK (0.56) | ALKIGF1RINSREGFRPTK2 | |
| SCHEMBL26655418 | 0.86 | ALK (0.65) | ALKIGF1RINSREGFRPTK2 | |
| SCHEMBL29661359 | 0.86 | ALK (0.65) | ALKIGF1RINSREGFRPTK2 | |
| SCHEMBL24327359 | 0.86 | ALK (0.69) | ALKIGF1RINSREGFRPTK2 | |
| SCHEMBL24327332 | 0.86 | ALK (0.67) | ALKIGF1RINSREGFRPTK2 | |
| SCHEMBL24327663 | 0.85 | ALK (0.59) | ALKIGF1RINSREGFRPTK2 | |
| SCHEMBL24327568 | 0.85 | ALK (0.71) | ALKIGF1RINSREGFRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | ALK 13/4885IGF1R 7/4885INSR 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.